Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

AVB-500/Paclitaxel Demonstrates Clinical Benefit in Platinum-Resistant Ovarian Cancer

March 23rd 2021

The GAS6/AXL inhibitor AVB-500, when combined with paclitaxel, elicited clinical benefit with favorable tolerability in patients with platinum-resistant ovarian cancer, according to data from a phase 1b study.

PARP Inhibition Presses Forward With the Possibility of Retreatment and Combo Approaches in Ovarian Cancer

March 23rd 2021

Jing-Yi Chern, MD, ScM, discusses the role of maintenance PARP inhibition in patients with recurrent platinum-sensitive ovarian cancer, as well as remaining questions regarding the utility of PARP inhibitors in this setting.

Olaparib Maintains Acceptable Safety Profile in Platinum-Sensitive, Relapsed Ovarian Cancer

March 22nd 2021

Olaparib, when used in patients with platinum-sensitive relapsed ovarian cancer who had a known BRCA mutation and homologous recombination deficiency status, demonstrated adverse effects that proved to be consistent with the established safety profile of the PARP inhibitor.

Maintenance Niraparib Maintains PFS Improvement in gBRCA+/- Ovarian Cancer

March 22nd 2021

Maintenance niraparib demonstrated clinical benefit that persisted beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations.  

Maintenance Olaparib Maintains PFS Benefit at 5 Years in Ovarian Cancer

March 21st 2021

Maintenance olaparib showcased progression-free survival benefit in almost half of the patients with ovarian cancer vs 21% of those who received placebo, including consistent benefit in high- and low-risk patients.

Niraparib/Bevacizumab Continues to Showcase PFS Benefit in Advanced Ovarian Cancer

March 21st 2021

Niraparib in combination with bevacizumab continued to showcase a progression-free survival benefit in patients with advanced ovarian cancer who previously received frontline platinum-based chemotherapy and bevacizumab.

Dostarlimab Triplet Shows Antitumor Activity, Tolerability in Ovarian Cancer

March 20th 2021

Dostarlimab plus niraparib and bevacizumab showcased favorable antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.

CA-125 Level Informs Surveillance Strategy for Olaparib/Bevacizumab in Ovarian Cancer

March 19th 2021

CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib and bevacizumab, according to an analysis from the phase 3 PAOLA-1.

Dr. Grisham on the Mechanism of Action of VS-6766 in Recurrent Low-Grade Serous Ovarian Cancer

March 19th 2021

Rachel N. Grisham, MD, discusses the mechanism of action of VS-6766 in patients with recurrent low-grade serous ovarian cancer.

Dr. George on Actionable Pathogenic Variants in Adults With Breast or Ovarian Cancers in the Caribbean

March 18th 2021

Sophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.

Monk and Herzog Hammer Out PARP Nuances in Ovarian Cancer

March 18th 2021

In our exclusive interview, Dr. Monk and Dr. Herzog discuss the importance of molecular testing in ovarian cancer and the utility of PARP inhibitor maintenance and treatment.

Immunotherapy Research Instigates More Questions Than Answers in Ovarian Cancer

March 15th 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses the basis for combining chemotherapy, PARP inhibitors, and VEGF inhibitors with immunotherapy in ovarian cancer and ongoing research with ADCs in the field.

1 in 7 Caribbean Adults With Breast or Ovarian Cancers Have Actionable Pathogenic Variants

March 10th 2021

One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.

FDA Grants Priority Review to Pafolacianine Sodium Injection in Ovarian Cancer

March 3rd 2021

The FDA has granted priority review to the new drug application for the novel compound pafolacianine sodium injection for use in the identification of ovarian cancer during surgery.

Dr. Krivak on the Importance of Germline Genetic Testing in Ovarian Cancer

March 1st 2021

Thomas C. Krivak, MD, discusses the importance of germline genetic testing in ovarian cancer.

Dr. Wenham on Rationale for Novel Immunotherapy Combos in Ovarian Cancer

February 24th 2021

Robert Wenham, MD, MS, FACOG, FACS, discusses novel immunotherapy combinations for the treatment of patients with ovarian cancer.

Phase 3 OVAL Trial of VB-111 in Platinum-Resistant Ovarian Cancer Gets Green Light to Continue

February 24th 2021

February 24, 2021 - An independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.

Novel CDH6-Targeted ADC DS-6000 Enters the Pipeline in RCC and Ovarian Cancer

February 23rd 2021

February 23, 2021 - The first patient in a first-in-human phase 1 study has been dosed with DS-6000, a novel CDH6-directed antibody-drug conjugate.

FDA Grants Fast Track Status to Immunotherapy GEN-1 in Advanced Ovarian Cancer

February 22nd 2021

February 22, 2021 - The FDA has granted a fast track designation to the DNA-mediated interleukin-12 immunotherapy GEN-1 for use in the treatment of patients with advanced ovarian cancer.

Germline Genetic Testing Gap Persists in Ovarian Cancer, More Delimited Panel Composition Needed to Improve Utility

February 16th 2021

February 16, 2021 - Only 34.3% of 14,689 patients with ovarian cancer received germline genetic testing between 2013 and 2019, revealing persistent underuse of testing among this population.